skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial

Review

(2375) Views  (698) Full article downloads

Authors: Ming-Sheng Zhou, Ivonne Hernandez Schulman

Published Date April 2009 Volume 2009:5 Pages 361 - 368
DOI: http://dx.doi.org/10.2147/VHRM.S4331

Ming-Sheng Zhou, Ivonne Hernandez Schulman

Nephrology-Hypertension Section, Veterans Affairs Medical Center and Division of Nephrology and Hypertension and Vascular Biology institute, University of Miami Miller School of Medicine, Miami, FL, USA

Abstract: A growing number of experimental and clinical studies have provided evidence indicating that pharmacological blockade of the renin–angiotensin system (RAS) by either angiotensin-converting enzyme inhibitors or angiotensin type 1 receptor blockers reduces the incidence of new onset type 2 diabetes in subjects with hypertension and/or cardiovascular disease, independently of antihypertensive and cardiovascular protective effects. The beneficial effects of RAS inhibition on the development of diabetes have been largely attributed to improvements in peripheral insulin sensitivity and glucose metabolism. This review focuses on recent experimental and clinical evidence supporting the role of RAS inhibition in the reduction of new onset type 2 diabetes and the mechanisms that may be involved.

Keywords: renin–angiotensin system, antihypertensive, diabetes








Readers of this article also read:

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Cardiovascular disease in patients with chronic kidney disease
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies
A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures
Insulin therapy in critically ill patients
Minimally invasive treatment of lumbar spinal stenosis with a novel interspinous spacer
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University